Skip to main content

Effect of Semaglutide on Dumping Syndrome and Post-Bariatric Hypoglycemia After Roux-en-Y Gastric Bypass: A Single-Center Retrospective Study

In brief

Semaglutide cut monthly hypoglycemic events by a third after gastric bypass

In a retrospective study of 100 adults with post-bariatric hypoglycemia or dumping syndrome, monthly clinically significant events fell from 4.9 to 3.3 over 12 months of semaglutide, while glucose-monitoring measures and symptom scores also improved. Responses varied: 15% had complete resolution, while 12% worsened. The findings support close monitoring, but a controlled study is needed to establish treatment benefit.

Journal
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (Q1)
Published
9 November 2026
Study design
Cohort / observational study
Evidence level
Level 3, Low (CEBM 3b)
Authors
Naseem Eisa, Mira Khoury
PMID
43003229
DOI
10.1016/j.eprac.2026.11.001

Why clinicians should know about it

Abstract

OBJECTIVES: To evaluate 12-month efficacy and safety of once-weekly semaglutide for refractory post-bariatric hypoglycemia (PBH)/dumping syndrome after Roux-en-Y gastric bypass (RYGB). METHODS: This single-center retrospective chart review included 100 adults at least 12 months post-RYGB completing 12 months of semaglutide (0.25-2.4 mg/week). Eligibility required Whipple-triad-compatible postprandial symptoms with ambulatory and/or mixed-meal tolerance test support, excluding fasting/non-bariatric hypoglycemia and non-standard anatomy. The primary endpoint was monthly clinically significant hypoglycemic events: Level 3 events requiring assistance and/or verified symptomatic Level 2 events (<54 mg/dL). RESULTS: Participants were 83.0% female, 42.7 ± 7.1 years old, and 2.8 ± 1.4 years post-RYGB; follow-up averaged 14.9 ± 1.8 months. Clinically significant hypoglycemic events decreased from 4.90 ± 2.12 to 3.26 ± 2.68/month at 12 months (p < 0.0001). Complete resolution occurred in 15%, ≥50% reduction without resolution in 26%, suboptimal response in 47%, and worsening hypoglycemia in 12%. Sigstad scores improved from 12.68 ± 2.63 to 9.13 ± 3.82 (p < 0.0001). CGM Time Below Range <54 mg/dL decreased from 5.06% to 2.58%, and Time In Range increased from 61.2% to 76.2% (both p < 0.0001). No serious adverse events occurred; nausea was most common (24.0%). CONCLUSIONS: Semaglutide was associated with fewer clinically significant hypoglycemic events, improved dumping symptoms, and better CGM metrics over 12 months. Variable response and worsening hypoglycemia in a minority support individualized titration and close monitoring.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.